Bottom line
Is FHCRX a good fund? The bottom line
FHCRX is the Fidelity Advisor Health Care Fund: Class Z share class of Health Care Portfolio, a managed health care sector mutual fund from Fidelity.
It charges 0.55% — about $55 a year on every $10,000 invested, cheaper than 80% of health care sector funds we track.
With $5.8 billion in net assets and 152 holdings, its largest position is ELI LILLY and CO (8.0%) and the top 10 make up 38.8% of the portfolio.
What stands out
- Low cost: cheaper than 80% of health care sector peers
Updated Nov 19, 2026
What FHCRX invests in
Health Care Portfolio seeks capital appreciation.
Normally investing at least 80% of assets in securities of companies principally engaged in the design, manufacture, or sale of products or services used for or in connection with health care or medicine. These companies may include, for example, companies engaged in the research, development, manufacturing, or marketing of products based on biotechnology research; companies engaged in research, development, or production of pharmaceuticals, including veterinary drugs; manufacturers, distributors, and wholesalers of health care equipment, devices, and supplies including drug delivery systems and eye care products; and owners and operators of health care facilities, HMOs, and other managed plans. For purposes of the fund's policy to normally invest at least 80% of its assets in securities of companies principally engaged in the business activity or activities identified for the fund…
From the fund's prospectus (filed Apr 24, 2026).
What FHCRX costs
On a $10,000 investment, FHCRX's 0.55% expense ratio costs about $55 a year. The prospectus estimates $689 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
FHCRX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | ELI LILLY and CO | 8.03% |
| 2 | Danaher Corp | 6.89% |
| 3 | JOHNSON and JOHNSON | 4.91% |
| 4 | Thermo Fisher Scientific Inc | 4.33% |
| 5 | Unitedhealth Group Inc | 3.49% |
| 6 | Alnylam Pharmaceuticals Inc | 2.40% |
| 7 | Gilead Sciences Inc | 2.21% |
| 8 | Boston Scientific Corp | 2.17% |
| 9 | Ascendis Pharma A/s | 2.17% |
| 10 | Fidelity Revere Street Trust | 2.17% |
Source: SEC Form N-PORT, period ended May 31, 2026
The top 10 make up 38.8% of the fund. See all top 25 holdings and asset mix →